Abstract

Matriptase, a type II trans-membrane serine protease of the S1 trypsin-like family, is expressed on the surface of nearly all normal human epithelium and found in biological fluid-like human milk. Matriptase overexpression has been implicated in tumor progression in certain epithelium-derived cancer cells. Matriptase is tightly regulated by its cognate inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1). It has been demonstrated that the Kunitz domain I (KD1) but not Kunitz domain II (KD2) of HAI-1 is responsible for the inhibitory activity of HAI-1 against matriptase. To investigate the molecular basis of inhibition of matriptase by HAI-1, we solved several crystal structures of matriptase serine protease domain in complex with the fragments of HAI-1. Based on these structures, we found that the binding of KD1 was different from previously predicted binding mode. The P3 arginine residue occupies the S3 specificity pocket of matriptase, but not the S4 pocket as in the cases of hepatocyte growth factor activator·HAI-1 KD1 and matriptase·sunflower trypsin inhibitor-1 complexes. The long 60-loop of matriptase makes direct contact with HAI-1 but remains flexible even in the complexes, and its apex does not bind with KD1 tightly. The interactions between this unique 60-loop and KD1 may provide an opportunity to increase the specificity and inhibitory activity of KD1 for matriptase. Furthermore, comparison between KD1 and a homology model of HAI-1 KD2 rationalizes the structural basis of why KD1 but not KD2 is responsible for the inhibitory activity of HAI-1 against matriptase.

Highlights

  • Matriptase requires very strict regulation by its inhibitor, hepatocyte growth factor activator inhibitor-1

  • Matriptase is tightly regulated by its cognate inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1)

  • It has been demonstrated that the Kunitz domain I (KD1) but not Kunitz domain II (KD2) of HAI-1 is responsible for the inhibitory activity of HAI-1 against matriptase

Read more

Summary

Background

Matriptase requires very strict regulation by its inhibitor, hepatocyte growth factor activator inhibitor-1. To investigate the molecular basis of inhibition of matriptase by HAI-1, we solved several crystal structures of matriptase serine protease domain in complex with the fragments of HAI-1. Based on these structures, we found that the binding of KD1 was different from previously predicted binding mode. The expression of matriptase has been demonstrated to be up-regulated in various cancer forms such as breast, cervix, ovaries, prostate, esophagus, and liver cancers (10 –19) Some of these cancers have been shown to be the results of the loss of balance between the protease and its cognate inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1), suggesting that matriptase requires very strict regulation by its inhibitor and serves as a potential anti-cancer therapeutic target. Homology modeling of HAI-1 KD2 based on KD1 structure elucidates the structural basis of selective inhibition of matriptase by KD1 but not KD2

EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
PDB code
Matriptase strongly prefers substrate with basic residues at
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call